Use of placebos in Phase 1 preventive HIV vaccine clinical trials

about

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.

P2860

Q35593139-DEEADD74-E652-4FCC-B865-64D6AA637A40

P2860

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

Item

http://www.wikidata.org/entity/Q36011214

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@ast

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@en

type

Item

label

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@ast

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@en

prefLabel

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@ast

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@en

P1476

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

@en

P2093

James G Kublin

http://www.w3.org/2001/XMLSchema#string

Martha Nason

http://www.w3.org/2001/XMLSchema#string

Nicole Frahm

http://www.w3.org/2001/XMLSchema#string

Paul T Edlefsen

http://www.w3.org/2001/XMLSchema#string

Peter B Gilbert

http://www.w3.org/2001/XMLSchema#string

Shelly T Karuna

http://www.w3.org/2001/XMLSchema#string

P2860

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Statistical evaluation of HIV vaccines in early clinical trials.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

When placebo controlled trials are essential and equivalence trials are inadequate.

Why use placebos in clinical trials? A narrative review of the methodological literature.

Placebo interventions, placebo effects and clinical practice.

Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.

Clinical trial structures

P304

749-752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2014.10.017

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25454855

http://www.w3.org/2001/XMLSchema#string

P921

placebo

phase I clinical trial

P932

4554766

http://www.w3.org/2001/XMLSchema#string

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

about

P2860

P2860

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932